TLSI · TriSalus Life Sciences, Inc. · Options Calculator
$4.76
+0.03 (+0.63%)
At close · Sep 9
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$307.87M
Shares
61.57M
Options Calculator
Theoretical estimateEstimate what a long-dated option on TLSI could return if you hold it and the stock reaches a target price. Premiums are theoretical Black-Scholes-Merton values — tune the inputs to match your broker, then compare each strike's return against simply holding the shares.
Best strike
—
Highest estimated return
Return at target
—
— annualized
Breakeven
—
Stock price to break even
Hold the stock
—
— annualized, with dividends
Return by strike at your target price
Strike ladder
| Strike | Moneyness | Premium | Breakeven | Value at target | Return | Annualized | Max loss |
|---|
Per share; one contract = 100 shares. Premiums are theoretical Black-Scholes-Merton estimates — real options are American-style and priced off an implied-volatility smile, so use your broker's quote for the actual premium. Not investment advice.
Loading strategy simulator…
Key facts
CIK
1826667
CUSIP
89680M101
13F (30d)
47 filings
47 filers
Visit website
Investor relations